Cabaletta Bio Inc (CABA) Stock Analysis
Verdict: WATCH (do not buy)
Rese-cel's mid-2027 myositis readout offers high upside, but a $40M quarterly burn creates dilution risk if trials delay.
Investment score: 40/100
Analysis as of
Is Cabaletta Bio Inc stock worth reviewing? AI model thesis
The model score of 40/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Cabaletta Bio Inc opportunities and risks
What speaks for CABA
- Mid-2027 Registrational Myositis Readout
What speaks against CABA
- Dilution and Cash Runway Tightness
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CABA | n/a | 0.0x | n/a | 0.0% | 0.0% | -45.7% |
| FENC | n/a | 6.2x | n/a | 93.7% | -5.5% | -0.6% |
| CCCC | n/a | 9.4x | n/a | 94.9% | -289.4% | -25.9% |
| RCEL | n/a | 3.9x | n/a | 81.6% | -57.0% | -8.0% |
| ZNTL | n/a | 0.0x | n/a | 0.0% | 0.0% | -83.8% |
| EBS | n/a | 0.5x | n/a | 49.4% | -23.0% | 24.5% |
| Peer median | n/a | 3.9x | n/a | 81.6% | -23.0% | -8.0% |
Frequently asked questions about Cabaletta Bio Inc (CABA)
Is CABA stock a good investment?
The cached TradeMates AI model rates Cabaletta Bio Inc as WATCH (do not buy) with an investment score of 40/100. The model score of 40/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is CABA stock a buy?
The TradeMates model verdict for CABA is WATCH (do not buy) with an investment score of 40/100. Treat this as a model signal to review, not a personal buy recommendation.